Allergic Conjunctivitis Pipeline Review, H2 2015
Summary
Global Markets Directs, Allergic Conjunctivitis Pipeline Review, H2 2015, provides an overview of the Allergic Conjunctivitiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Allergic Conjunctivitis Overview 7
Therapeutics Development 8
Pipeline Products for Allergic Conjunctivitis - Overview 8
Allergic Conjunctivitis - Therapeutics under Development by Companies 9
Allergic Conjunctivitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Allergic Conjunctivitis - Products under Development by Companies 13
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 14
Accolade Pharma LLC 14
Akari Therapeutics, Plc 15
Aldeyra Therapeutics, Inc. 16
Allergan Plc 17
Eleven Biotherapeutics Inc. 18
Griffin Discoveries BV 19
NicOx S.A. 20
Ocular Therapeutix, Inc. 21
Ohr Pharmaceutical Inc. 22
Oxagen Limited 23
Sylentis S.A. 24
Xencor, Inc. 25
Allergic Conjunctivitis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AGN-229666 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AL-53817 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cetirizine hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
dexamethasone acetate SR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs for Allergic Conjunctivitis - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GD-134 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GD-136 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
isunakinra - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KBP-7306 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NS-2 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
OC-2417 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OPX-1 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Antagonize Histamine H1/H4 Receptor for Ophthalmology and Asthma - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SYL-116011 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
XmAb-7195 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Zafi-2 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Allergic Conjunctivitis - Recent Pipeline Updates 53
Allergic Conjunctivitis - Dormant Projects 66
Allergic Conjunctivitis - Discontinued Products 67
Allergic Conjunctivitis - Product Development Milestones 68
Featured News & Press Releases 68
Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis 68
Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 68
Oct 15, 2015: Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis 70
Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial 70
Aug 12, 2015: Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis 70
Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 71
May 07, 2015: Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting 72
Apr 29, 2015: Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis 73
Apr 22, 2015: Eleven Biotherapeutics Presents Clinical Data on EBI-005 at the ARVO 2015 Annual Meeting 74
Apr 16, 2015: Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77
List Of Tables
Number of Products under Development for Allergic Conjunctivitis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Allergic Conjunctivitis - Pipeline by Accolade Pharma LLC, H2 2015 14
Allergic Conjunctivitis - Pipeline by Akari Therapeutics, Plc, H2 2015 15
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015 16
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2015 17
Allergic Conjunctivitis - Pipeline by Eleven Biotherapeutics Inc., H2 2015 18
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2015 19
Allergic Conjunctivitis - Pipeline by NicOx S.A., H2 2015 20
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2015 21
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2015 22
Allergic Conjunctivitis - Pipeline by Oxagen Limited, H2 2015 23
Allergic Conjunctivitis - Pipeline by Sylentis S.A., H2 2015 24
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015 53
Allergic Conjunctivitis - Dormant Projects, H2 2015 66
Allergic Conjunctivitis - Discontinued Products, H2 2015 67
List Of Figures
Number of Products under Development for Allergic Conjunctivitis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Top 10 Targets, H2 2015 27
Number of Products by Stage and Top 10 Targets, H2 2015 27
Number of Products by Mechanism of Actions, H2 2015 29
Number of Products by Stage and Mechanism of Actions, H2 2015 29
Number of Products by Routes of Administration, H2 2015 31
Number of Products by Stage and Routes of Administration, H2 2015 31
Number of Products by Molecule Types, H2 2015 33
Number of Products by Stage and Molecule Types, H2 2015 33
